| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
MapLight Therapeutics, Inc.$39.32
-0.48 (-1.21%)
D 35Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.23 B
EPS
-4.52
P/E Ratio
-
Value Trade
5.30 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
53.68 M
Operating CF
-51.18 M
Total Assets
418.79 M
Total Liabilities
18.95 M
Equity
399.83 M
D/E Ratio
12,345
1.02 %
Week
2.1 %
1 Month
61.61 %
3 Month
105.95 %
6 Month
51.32 %
5 Year
51.32 %
All Time
Cash Data
Cash Position
310.11 M
Monthly Burn
17.06 M
Runway
16.5 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.18 M
52 Week Range
12.24 - 33.28
% held by Insiders
82.02 %
% held by Institutions
30.48 %
Enterprise Value
920.75 M
Total Shares
45.40 M
Short %
13.82 %
Float Shares
18.66 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $56M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 911)
Percentile RankMapLight Therapeutics, Inc. faces pipeline headwinds (35/100), with $168M risk-adjusted pipeline value, led by ML-007C-MA in Schizophrenia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ML-007C-MA Small molecule | Schizophrenia | Phase 2 | NCT07038876 | 12% | $108M | COMPLETED | 807 | FAST | B (76) | Jun 11, 2026 | MODERATE_RISK | HIGH Jul 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ML-004 | Autism Spectrum Disorder | Phase 2 | 2026-06-22 | secondary: ABC I effect size 1.33, nominal p value 0.013, CGI I effect size 1.08, nominal p value 0.036 Read More | MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder Read More | |
ML-004 | Autism Spectrum Disorder | Phase 2 | 2026-06-22 | secondary: ABC I effect size 1.33, nominal p value 0.013, CGI I effect size 1.08, nominal p value 0.036 Read More | MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder Read More | |
ML-004 | Autism Spectrum Disorder | Phase 2 | 2026-06-22 | secondary: ABC I effect size 1.33, nominal p value 0.013, CGI I effect size 1.08, nominal p value 0.036 Read More | MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MPLT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MPLT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MPLT▲ +7%on this news· ran to +20% by day 3
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics has appointed Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler will serve on the Audit Committee, while Cox will chair the Nominating and Corporate Governance Committee. The company aims to enhance its strategy for developing therapies for CNS disorders with their leadership.
Read more →MPLTMapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
MapLight Therapeutics announced topline results from the Phase 2 IRIS study of ML-004 in autism spectrum disorder (ASD). While the study did not meet its primary endpoint related to social communication, it showed promising results in reducing irritability among adolescents with moderate to severe baseline irritability. The company plans to discuss the results with the FDA to determine the next steps in clinical development.
Read more →MPLTMapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-Au
MapLight Therapeutics announced its financial results for Q1 2026, highlighting the completion of enrollment in its Phase 2 ZEPHYR trial for schizophrenia and the IRIS trial for autism spectrum disorder, with topline results expected by mid-August 2026. The company reported a cash position of $395.2 million, projected to sustain operations through 2027. However, despite promising clinical developments, the company incurred a net loss of $60.7 million in the quarter, reflecting rising R&D costs and operational expenses. Ongoing trials also include the VISTA trial for Alzheimer's disease psychosis, with expectations for results in the second half of 2027.
Read more →MPLT▼ -6.2%on this news
MapLight Therapeutics to Participate in Upcoming Investor Conferences
MapLight Therapeutics, Inc. announced its participation in two upcoming investor conferences: the 2026 RBCCM Global Healthcare Conference on May 19 and the 2026 Jefferies Global Healthcare Conference on June 3. The management team will present and host one-on-one meetings at both events. The company aims to improve treatments for central nervous system disorders.
Read more →MPLTMapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight Therapeutics has completed enrollment in its Phase 2 ZEPHYR trial for ML-007C-MA, aimed at treating schizophrenia. Additionally, the final patient visit for the IRIS trial of ML-004 in autism spectrum disorder has been completed. Topline results from both trials are expected by mid-August 2026, highlighting the company's commitment to addressing critical mental health needs.
Read more →MPLT▲ +6%on this news
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics reported its financial results for Q4 and full year 2025, highlighting key developments in its clinical trials. The Phase 2 ZEPHYR trial for schizophrenia is on track for target enrollment by April 2026, while topline results for both the ZEPHYR and IRIS trials are expected in Q3 2026. Additionally, the company received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis, with a strong cash position to support ongoing operations.
Read more →MPLTMapLight Therapeutics to Participate in Upcoming March 2026 Investor Conferences
MapLight Therapeutics announced its participation in several upcoming investor conferences in March 2026. The events include the Jefferies Biotech on the Beach Summit, the Leerink Global Healthcare Conference, and the Stifel Virtual CNS Forum. The company aims to engage with investors through presentations and one-on-one meetings, highlighting its focus on central nervous system disorders.
Read more →MPLTMapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics has updated the expected timing for topline results from its Phase 2 ZEPHYR and IRIS studies to Q3 2026. The ZEPHYR trial, focusing on ML-007C-MA for schizophrenia, is enrolling participants rapidly. Additionally, the IRIS trial for autism spectrum disorder has completed enrollment, also targeting results in the same timeframe.
Read more →MPLTxfeff; This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company&
MapLight Therapeutics presented updates on its product candidates during a corporate presentation on January 9, 2026. The company focuses on developing novel treatments for CNS disorders, including schizophrenia and Alzheimer's disease psychosis. Their leading asset includes ML-007C-MA, which is currently in Phase 2 trials with results anticipated in Q3 2026. With approximately $450M in cash, MapLight aims to advance its diversified pipeline despite inherent developmental risks and uncertainties.
Read more →MPLTMapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
MapLight Therapeutics has received Fast Track designation from the FDA for its investigational drug ML-007C-MA, aimed at treating hallucinations and delusions associated with Alzheimer's disease psychosis. This designation highlights the urgent need for effective treatments in this area. The company is currently conducting a Phase 2 clinical trial, expecting to enroll 300 participants and report results in late 2027.
Read more →MPLT▲ +8.4%on this news
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress • Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026  
MapLight Therapeutics reported strong financial results for Q3 2025, highlighted by a successful $296.5 million IPO which positions the company well through 2027. The company is advancing its drug candidates, with Phase 2 ZEPHYR and VISTA trials expected to yield results in 2026 and 2027 respectively for schizophrenia and Alzheimer's disease psychosis. Despite this progress, the company recorded a net loss of $29.4 million in Q3 2025, reflecting ongoing financial challenges associated with clinical trials and regulatory processes.
Read more →MPLTFORM OF SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this " Agreement ") is entered into as of
MapLight Therapeutics, Inc. has entered into a Share Purchase Agreement with an unnamed Investor, proposing the sale of the Company's common stock in conjunction with an upcoming initial public offering (IPO). The Agreement outlines the terms for the Offering, which will occur concurrently with the IPO at the determined IPO price. Additionally, it specifies conditions regarding payment and delivery of shares to the Investor following the IPO Closing Time.
Read more →MPLTMapLight Therapeutics Announces Commencement of Initial Public Offering
MapLight Therapeutics has announced the commencement of its initial public offering (IPO), planning to offer 14,750,000 shares at $17.00 each. Additionally, a concurrent private placement of 476,707 shares is proposed. The registration statement is expected to become effective on October 26, 2025, allowing the company to proceed with its IPO plans.
Read more →MPLTMapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M₁/M₄ Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer’s Disease Psychosis
MapLight Therapeutics has initiated a Phase 2 trial for ML-007C-MA, a novel M1/M4 muscarinic agonist, targeting Alzheimer’s disease psychosis (ADP). This study, named VISTA, follows a successful Phase 1 program and aims to evaluate the drug's efficacy and safety in approximately 300 patients. The trial addresses the lack of FDA-approved treatments for ADP, which affects many Alzheimer's patients.
Read more →MPLTMapLight Therapeutics Announces $372.5 Million Series D Financing
MapLight Therapeutics has announced a successful $372.5 million Series D financing, co-led by Forbion and Goldman Sachs. This funding will support the ongoing Phase 2 trials of their lead program, ML-007C-MA, aimed at treating schizophrenia and Alzheimer's disease psychosis. The financing reflects strong investor confidence in MapLight's innovative approach to CNS disorders.
Read more →MPLTMapLight Therapeutics Announces Initiation of Phase 2 Trial of Its Novel M₁/M₄ Muscarinic Agonist ML-007C-MA for the Treatment of Schizophrenia
MapLight Therapeutics has initiated a Phase 2 trial for ML-007C-MA, a novel M1/M4 muscarinic agonist aimed at treating schizophrenia. The ZEPHYR study will evaluate the drug's efficacy, safety, and tolerability in approximately 300 patients experiencing acute symptoms. This trial follows promising Phase 1 results, highlighting the need for innovative treatments in this area.
Read more →MPLTMapLight Therapeutics Announces Results from Phase 1 Trial
MapLight Therapeutics announced positive results from its Phase 1 trial of ML-007/PAC, a novel muscarinic agonist for treating schizophrenia and Alzheimer's disease psychosis. The trial demonstrated a favorable safety and tolerability profile, with no severe adverse events reported. The company plans to initiate Phase 2 trials in early 2025, aiming to improve treatment options for patients.
Read more →MPLTMapLight Therapeutics Appoints Maria Walker to Board of Directors
MapLight Therapeutics has appointed Maria Walker to its Board of Directors. With over 30 years of experience in investment and advisory roles, Walker is expected to contribute significantly to the company's growth. She will also serve on the audit committee as MapLight prepares to advance its pipeline asset, ML-007/PAC, into Phase 2 clinical trials.
Read more →MPLTMapLight Therapeutics Announces Initiation of Phase 1 Clinical Trial for ML-007/PAC, Under Development for Schizophrenia and Alzheimer’s Disease Psychosis
MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis. This trial will assess the safety and tolerability of the drug in both non-elderly and elderly adults. The results will inform future Phase 2 trials, addressing significant unmet needs in these conditions.
Read more →MPLTMapLight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
MapLight Therapeutics has appointed Vishwas Setia as Chief Financial Officer, succeeding Jonathan Gillis, who will become Chief Administrative and Accounting Officer. This leadership change is aimed at supporting the company's growth and development, particularly as it advances its pipeline targeting treatments for schizophrenia and Alzheimer's disease psychosis. Setia brings significant experience in capital markets and strategic transactions.
Read more →MPLTMapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M₁/M₄ Muscarinic Agonist in Development for Schizophrenia and Alzheimer’s Disease Psychosis
MapLight Therapeutics has completed a Phase 1 clinical trial for ML-007, a novel M1/M4 muscarinic agonist, demonstrating its safety and tolerability in healthy volunteers. The trial showed that ML-007 was well tolerated at all doses, with no serious adverse events reported. The company plans to advance to Phase 2 trials in 2024, focusing on treating schizophrenia and Alzheimer's disease psychosis.
Read more →MPLTMapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of CNS Therapeutics
MapLight Therapeutics has successfully closed a $225 million Series C funding round, aimed at advancing its pipeline of CNS therapeutics. The funding will support the development of ML-007C-MA in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis in 2024. This financing round attracted new investors, including Novo Holdings and Cowen Healthcare Investments, validating MapLight's innovative approach to neuropsychiatric treatments.
Read more →MPLTSuccessful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007
MapLight Therapeutics has successfully completed its second Phase 1 clinical trial for ML-007, a novel muscarinic receptor agonist. The trial involved 106 subjects and assessed safety, tolerability, and pharmacokinetics. Results indicated that ML-007 was safe and well tolerated, with plans to advance to Phase 2 in 2024 for a combination tablet formulation. The findings support twice daily dosing across various age groups.
Read more →MPLTMapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors
MapLight Therapeutics has appointed Dr. Tim Garnett to its Board of Directors. Dr. Garnett brings decades of experience in drug development and strategic management, particularly in neuroscience. His leadership is expected to bolster MapLight's efforts in advancing its pipeline of therapeutics for neurodegenerative and neurocognitive disorders. The company aims to improve treatment options for challenging brain disorders.
Read more →Competitive Position
How MPLT ranks across every disease it competes inCompetitive Position is a premium feature
See how MPLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial